DDrare: Database of Drug Development for Rare Diseases

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-[N-metil-11C1-PK11195(PK); 18F-AV-1451; 18F-AV-45; 18F-FDG; 18F-RO6958948; AL; AL001; AMIODARONE; Amantadine; Amiodarone; Amyvid; BIIB092; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: ECOCAPTURE; Behavioral: ICM_APATHY_TASKS; C-11 PiB; Carbonate; Chloride; Citalopram; Davunetide; Davunetide (AL-108, NAP); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Donepezil; EVP-0334; F 18 T807; F-18; F-18 FDG; FRM-0334; Ferulic acid; Florbetapir (18F); Florbetapir 18F; Florbetapir 18F Injection; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Galantamine; Galantamine hydrobromide; Histone Deacetylase Inhibitor; Intranasal oxytocin; LMTM; LMTM/TRx0237; Leucine; Leuco-methylthioninium bis(hydromethanesulfonate); Lithium Carbonate; Lithium carbonate; MTC TRx0014-001 capsules; Memantine; Memantine hydrochloride; Metformin; Methylprednisolone; Methylthioninium; Methylthioninium chloride; N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); Neurohormonal mechanisms; Novolin-R insulin; Other: 13C6 Leucine; Other: MRI; Oxytocin; PEA-LUT; PR006; Phenothiazine; Pittsburgh Compound B; Pittsburgh Compound B (C-11 PiB); Prednisone; Procedure: Brain PET scan; Saline Nasal Mist; Sirolimus; Syntocinon; T807; TRx0237; Tau (18-F-AV-1451); Tolcapone; Vizamyl; Vizamyl (flutemetamol(F-18)); [18F]PI-2620

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03260920 (ClinicalTrials.gov)	January 31, 2018	19/7/2017	Intranasal Oxytocin for Frontotemporal Dementia	A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia	Frontotemporal Dementia	Drug: Syntocinon	Lawson Health Research Institute	Weston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry Consultants	Recruiting	30 Years	80 Years	All	112	Phase 2	United States;Canada
2	NCT01937013 (ClinicalTrials.gov)	September 12, 2013	3/9/2013	Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia	Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia	Frontotemporal Dementia	Drug: Intranasal oxytocin;Drug: Saline Nasal Mist	Lawson Health Research Institute	Canadian Institutes of Health Research (CIHR)	Completed	30 Years	85 Years	All	52	Phase 2	Canada
3	NCT01386333 (ClinicalTrials.gov)	June 2011	29/6/2011	Safety Study of Intranasal Oxytocin in Frontotemporal Dementia	A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF	Frontotemporal Dementia	Drug: oxytocin;Drug: Saline Nasal Mist	Lawson Health Research Institute	The Consortium of Canadian Centres for Clinical Cognitive Research (C5R)	Completed	30 Years	80 Years	Both	23	Phase 1	Canada
4	NCT01002300 (ClinicalTrials.gov)	September 2009	23/10/2009	Oxytocin and Social Cognition in Frontotemporal Dementia	Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia	Frontotemporal Dementia;Pick's Disease	Drug: intranasal oxytocin	Lawson Health Research Institute	The Alzheimer Society London and Middlesex	Completed	30 Years	80 Years	Both	24	N/A	Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03260920
(ClinicalTrials.gov)

January 31, 2018

19/7/2017

Intranasal Oxytocin for Frontotemporal Dementia

A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia

Frontotemporal Dementia

Drug: Syntocinon

Lawson Health Research Institute

Weston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry Consultants

Recruiting

30 Years

80 Years

All

112

Phase 2

United States;Canada

NCT01937013
(ClinicalTrials.gov)

September 12, 2013

3/9/2013

Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia

Frontotemporal Dementia

Drug: Intranasal oxytocin;Drug: Saline Nasal Mist

Lawson Health Research Institute

Canadian Institutes of Health Research (CIHR)

Completed

30 Years

85 Years

All

Phase 2

Canada

NCT01386333
(ClinicalTrials.gov)

June 2011

29/6/2011

Safety Study of Intranasal Oxytocin in Frontotemporal Dementia

A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF

Frontotemporal Dementia

Drug: oxytocin;Drug: Saline Nasal Mist

Lawson Health Research Institute

The Consortium of Canadian Centres for Clinical Cognitive Research (C5R)

Completed

30 Years

80 Years

Both

Phase 1

Canada

NCT01002300
(ClinicalTrials.gov)

September 2009

23/10/2009

Oxytocin and Social Cognition in Frontotemporal Dementia

Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia

Frontotemporal Dementia;Pick's Disease

Drug: intranasal oxytocin

Lawson Health Research Institute

The Alzheimer Society London and Middlesex

Completed

30 Years

80 Years

Both

N/A

Canada